FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of Pemgarda™ (Pemivibart) to Include Treatment of Mild-to-Moderate Covid-19 for Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing Pemgarda Eua for Pre-Exposure Prophylaxis of Covid-19 in Certain Immunocompromised Patients
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.